Prevalence of Different Subtypes of Renal Cell Carcinoma among Patients who have Undergone Nephrectomy; Statistics of a Referral Medical Center in Iran
Men's Health Journal,
Vol. 5 No. 1 (2021),
6 January 2021
,
Page e10
https://doi.org/10.22037/mhj.v5i1.34251
Abstract
Renal cell carcinoma (RCC) is the third most common genitourinary cancer in the world, and has the highest mortality rates among these types of cancers. In the present cross-sectional assessment, the prevalence of RCC subtypes in a sample of Iranian patients diagnosed with RCC which have undergone nephrectomy surgery between years 2014 to 2019 in a referral medical center has been investigated. We have studied 68 patients, including 47 male and 21 female individuals with an average age of 55. The patients have been studied for demographic and pathologic information such as age, sex, tumor size, tumor subtype, TNM staging, Fuhrman nuclear grading, and other pathological information. The statistical analysis was done via SPSS software version 21. Quantitative data were examined by T test and qualitative data were assessed by Chi square test. As we observed in the results, the most common RCC subtype among these patients was clear cell 53%, followed by papillary 22% and chromophobe 19%, emphasizing the higher rates of chromophobe RCC compared to the statistics worldwide.
- Renal Cell Carcinoma
- Nephrectomy
- Pathology
- Chromophobe Renal Cell Carcinoma
- Clear Cell Renal Cell Carcinoma
- Histology
How to Cite
References
2. Lopez-Beltran A, Scarpelli M, Montironi R, Kirkali Z. 2004 WHO classification of the renal tumors of the adults. European urology. 2006;49(5):798-805.
3. Russo P, Jang TL, Pettus JA, Huang WC, Eggener SE, O'Brien MF, et al. Survival rates after resection for localized kidney cancer: 1989 to 2004. Cancer. 2008;113(1):84-96.
4. Cairns P. Renal cell carcinoma. Cancer biomarkers. 2011;9(1-6):461-73.
5. Zhou H, Zheng S, Truong LD, Ro JY, Ayala AG, Shen SS. Clear cell papillary renal cell carcinoma is the fourth most common histologic type of renal cell carcinoma in 290 consecutive nephrectomies for renal cell carcinoma. Human pathology. 2014;45(1):59-64.
6. Lau WK, Cheville JC, Blute ML, Weaver AL, Zincke H. Prognostic features of pathologic stage T1 renal cell carcinoma after radical nephrectomy. Urology. 2002;59(4):532-7.
7. Vijayalakshmi K, Shankar V, Bain RM, Nolley R, Sonn GA, Kao CS, et al. Identification of diagnostic metabolic signatures in clear cell renal cell carcinoma using mass spectrometry imaging. International journal of cancer. 2020;147(1):256-65.
8. Lucca I, Klatte T, Fajkovic H, De Martino M, Shariat SF. Gender differences in incidence and outcomes of urothelial and kidney cancer. Nature Reviews Urology. 2015;12(10):585.
9. Nicodemus KK, Sweeney C, Folsom AR. Evaluation of dietary, medical and lifestyle risk factors for incident kidney cancer in postmenopausal women. International journal of cancer. 2004;108(1):115-21.
10. Leibovich BC, Lohse CM, Crispen PL, Boorjian SA, Thompson RH, Blute ML, et al. Histological subtype is an independent predictor of outcome for patients with renal cell carcinoma. The Journal of urology. 2010;183(4):1309-16.
11. Lipworth L, Morgans AK, Edwards TL, Barocas DA, Chang SS, Herrell SD, et al. Renal cell cancer histological subtype distribution differs by race and sex. BJU international. 2016;117(2):260-5.
12. Qi P, Tsivian M, Abern MR, Passoni NM, McGinley KF, Polascik TJ, editors. Clinicopathological characteristics and outcomes of surgically excised renal masses in African Americans. Urologic Oncology: Seminars and Original Investigations; 2014: Elsevier.
13. Wu J, Zhang P, Zhang G, Wang H, Gu W, Dai B, et al. Renal cell carcinoma histological subtype distribution differs by age, gender, and tumor size in coastal Chinese patients. Oncotarget. 2017;8(42):71797.
14. Chin AI, Lam JS, Figlin RA, Belldegrun AS. Surveillance strategies for renal cell carcinoma patients following nephrectomy. Reviews in urology. 2006;8(1):1.
15. Lam JS, Belldegrun AS, Figlin RA. Advances in immune-based therapies of renal cell carcinoma. Expert review of anticancer therapy. 2004;4(6):1081-96.
16. Marchioni M, Preisser F, Bandini M, Nazzani S, Tian Z, Kapoor A, et al. Comparison of partial versus radical nephrectomy effect on other-cause mortality, cancer-specific mortality, and 30-day mortality in patients older than 75 years. European urology focus. 2019;5(3):467-73.
- Abstract Viewed: 133 times
- pdf Downloaded: 141 times